GlassScriptPhysician profile
Jesse W Adams
NPI 1851479554
$4,542.36
in general payments reported to CMS, 2019-2025
20 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,350 · 2020: $336 · 2021: $1,093 · 2023: $258 · 2024: $360 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $528.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $496.82 | 2019-2024 | Imfinzi |
| Alexion Pharmaceuticals, INC. | $370.80 | 2019-2021 | |
| Celgene Corporation | $355.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $348.92 | 2019-2023 | Reblozyl |
| Genentech USA, INC. | $250.86 | 2019 | |
| Eisai INC. | $240.47 | 2019-2020 | |
| Beigene USA, INC. | $240.37 | 2021-2024 | Brukinsa |
| Daiichi Sankyo INC. | $227.73 | 2021 | |
| Pfizer INC. | $214.46 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.28 | 2019 | |
| Amgen INC. | $193.22 | 2019-2020 | |
| Beone Medicines USA, INC. | $124.77 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $124.08 | 2019 | |
| Epizyme, INC. | $123.50 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $122.95 | 2023 | Tecvayli, Carvykti, Darzalex |
| Glaxosmithkline, LLC. | $119.82 | 2020 | |
| Puma Biotechnology, INC. | $117.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.51 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.